What is OmniAb?
Founded in 2007, OmniAb operates as a specialized biotechnology research and development entity, providing the pharmaceutical industry with a comprehensive suite of antibody discovery platforms. The company's core value proposition lies in its proprietary transgenic animal technologies, including OmniRat, OmniChicken, and OmniMouse, which are engineered to produce human-sequence antibodies. This biological foundation is augmented by advanced immunization methods and high-throughput screening, allowing for the rapid identification of therapeutic candidates.
Beyond its wet-lab capabilities, OmniAb has integrated computational antigen design and the OmniDeep platform to optimize therapeutic discovery. This dual-pronged approach enables the company to support a wide array of antibody modalities, including complex bispecific antibodies and antibody-drug conjugates. By offering these customizable, high-precision tools, OmniAb serves as a critical infrastructure provider for global pharmaceutical firms seeking to streamline their drug development pipelines and improve the efficacy of next-generation therapeutics.
How much funding has OmniAb raised?
OmniAb has raised a total of $30M across 1 funding round:
Stock/Share Issuance
$30M
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Key Investors in OmniAb
OmniAb
Undisclosed investor participating in the funding round.
What's next for OmniAb?
With the recent strategic investment, OmniAb is well-positioned to deepen its penetration into the global pharmaceutical R&D market. The company's roadmap likely involves the further refinement of its transgenic platforms and the expansion of its computational discovery tools to address increasingly complex disease targets. As the industry shifts toward more personalized and targeted therapies, OmniAb's ability to provide scalable, high-quality antibody sequences will be a key driver of its long-term growth.
Strategic priorities will likely focus on enhancing the throughput of its discovery engines and fostering deeper collaborations with major pharmaceutical partners. By maintaining its focus on technological differentiation and operational excellence, OmniAb is poised to capitalize on the growing demand for efficient, reliable, and innovative antibody development solutions, solidifying its role as an essential partner in the global drug discovery ecosystem.
